Martin P Keough

Title: Martin P. Keough: Innovator in Peptide Compounds for FGF Receptor Modulation

Introduction: Martin P. Keough, an inventor based in Abington, MA, is recognized for his significant contribution to the field of biotechnology through his innovative patent. His work primarily focuses on the development of peptide compounds that play a crucial role in modulating fibroblast growth factor receptor (FGFR) activity.

Latest Patents: Martin holds a patent that involves peptide compounds designed to bind to either fibroblast growth factors (FGFs) or fibroblast growth factor receptors (FGFRs). The groundbreaking invention includes methods of modulating FGFR activity, particularly involving FGFR2-IIIC and basic FGF. The patent features a specific amino acid sequence: (Y/F)-(L/F/I)-(R/D/E/S/Y/G)-(Q/L/Y)-Y-(M/L/K/R)-(L/M/D/E/N/S)-(R/L/S/T)-(L/F/M/V) (SEQ ID NO: 1). Additionally, it encompasses pharmaceutical compositions that integrate these peptide compounds with a pharmaceutically acceptable carrier.

Career Highlights: Martin P. Keough is currently affiliated with Praecis Pharmaceuticals, Inc., where he utilizes his expertise to push the boundaries of medical science through his innovative research. His patent underscores his dedication to advancing therapeutic strategies aimed at FGFR activity modulation.

Collaborations: Throughout his career, Martin has collaborated with notable colleagues, including Howard Benjamin and Ling Chai. These partnerships have contributed to the amplification of his research and the successful development of novel biotechnological applications.

Conclusion: Martin P. Keough's inventive contributions in the realm of peptide compounds have the potential to enhance medical treatments and provide novel approaches to managing diseases associated with FGF receptor activity. His ongoing research and collaborations continue to pave the way for future innovations in biotechnology.